Abstract
Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients’ outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.
Original language | English |
---|---|
Pages (from-to) | 1425-1429 |
Number of pages | 5 |
Journal | Clinical and Translational Oncology |
Volume | 22 |
Issue number | 9 |
DOIs | |
Publication status | Published - 1 Sept 2020 |
Externally published | Yes |
Keywords
- ALK
- Liquid biopsy
- Next-generation
- Non-small cell lung cancer
- Sequential treatment